Published in Mol Med on April 01, 1997
Interactions of the innate and adaptive arms of the immune system in the pathogenesis of spondyloarthritis. Clin Exp Rheumatol (2011) 1.45
Activation of B cells by antigens on follicular dendritic cells. Trends Immunol (2010) 0.99
Clonally-related immunoglobulin VH domains and nonrandom use of DH gene segments in rheumatoid arthritis synovium. Mol Med (1998) 0.86
Intraclonal generation of antibody mutants in germinal centres. Nature (1991) 7.39
Antigens in immunity. XV. Ultrastructural features of antigen capture in primary and secondary lymphoid follicles. J Exp Med (1968) 6.56
Cell selection by antigen in the immune response. Adv Immunol (1969) 6.05
Maturation of the immune response in germinal centers. Cell (1991) 5.68
Natural autoantibodies: from 'horror autotoxicus' to 'gnothi seauton'. Immunol Today (1991) 3.35
Antigen-induced B-cell death and elimination during germinal-centre immune responses. Nature (1995) 2.95
Soluble antigen can cause enhanced apoptosis of germinal-centre B cells. Nature (1995) 2.65
Germinal centres in T-cell-dependent antibody responses. Immunol Today (1992) 2.47
Genetic and structural evidence for antigen selection of anti-DNA antibodies. Annu Rev Immunol (1994) 2.45
Differentiation of B cells in the nonlymphoid tissue of the synovial membrane of patients with rheumatoid arthritis. Proc Natl Acad Sci U S A (1996) 2.36
Increased frequency of rheumatoid factor precursor B lymphocytes after immunization of normal adults with tetanus toxoid. Clin Exp Immunol (1983) 1.88
Human IgM+IgD+ B cells, the major B cell subset in the peripheral blood, express V kappa genes with no or little somatic mutation throughout life. Eur J Immunol (1993) 1.85
Detection of Chlamydia trachomatis DNA in joints of reactive arthritis patients by polymerase chain reaction. Lancet (1992) 1.83
Immunohistologic characterization of synovial membrane lymphocytes in rheumatoid arthritis. Arthritis Rheum (1984) 1.65
Clonally related IgM rheumatoid factors undergo affinity maturation in the rheumatoid synovial tissue. J Immunol (1992) 1.55
The identification of germinal centres and follicular dendritic cell networks in rheumatoid synovial tissue. Scand J Immunol (1995) 1.47
Alteration of Chlamydia trachomatis biologic behavior in synovial membranes. Suppression of surface antigen production in reactive arthritis and Reiter's syndrome. Arthritis Rheum (1995) 1.43
Molecular evidence for the presence of chlamydia in the synovium of patients with Reiter's syndrome. Arthritis Rheum (1992) 1.22
Chlamydial rRNA in the joints of patients with Chlamydia-induced arthritis and undifferentiated arthritis. Clin Exp Rheumatol (1992) 1.09
High affinity, thyroid-specific human autoantibodies displayed on the surface of filamentous phage use V genes similar to other autoantibodies. J Immunol (1993) 1.09
Structure of the VH and VL segments of monoreactive and polyreactive IgA autoantibodies to DNA in patients with systemic lupus erythematosus. J Immunol (1994) 1.08
Control of autoantibody affinity by selection against amino acid replacements in the complementarity-determining regions. Proc Natl Acad Sci U S A (1994) 1.07
Activation of an excluded immunoglobulin allele in a human B lymphoma cell line. Science (1989) 1.07
The B lymphocyte in rheumatoid arthritis: analysis of rearranged V kappa genes from B cells infiltrating the synovial membrane. Eur J Immunol (1995) 1.05
Individual germinal centres of myasthenia gravis human thymuses contain polyclonal activated B cells that express all the Vh and Vk families. Clin Exp Immunol (1991) 0.99
Recent advances in the pathogenesis of reactive arthritis. Immunol Today (1996) 0.92
Characterization of a new subgroup of human Ig V lambda cDNA clone and its expression. Mol Immunol (1992) 0.83
Immunoglobulin variable gene analysis of human autoantibodies reveals antigen-driven immune response to glutamate decarboxylase in type 1 diabetes mellitus. Eur J Immunol (1995) 0.81
Evidence for an antigen-driven selection process in human autoantibodies against acetylcholine receptor. Mol Immunol (1995) 0.79
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis (2009) 8.37
Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum (1998) 6.16
Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet (2002) 6.12
The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis (2010) 5.24
2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis (2011) 4.78
Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum (2000) 4.62
Somatic mutation and the maturation of immune response to 2-phenyl oxazolone. Nature (1984) 4.45
ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis (2005) 4.31
Mutation drift and repertoire shift in the maturation of the immune response. Immunol Rev (1987) 4.16
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis (2009) 3.32
Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis (2008) 3.17
Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group. Ann Rheum Dis (2009) 3.15
Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum (1995) 3.10
Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum (2003) 2.91
How to diagnose axial spondyloarthritis early. Ann Rheum Dis (2004) 2.91
International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis (2003) 2.85
Molecular events during maturation of the immune response to oxazolone. Nature (1985) 2.78
Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum (2003) 2.78
European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis (2011) 2.74
Divergent T-cell cytokine patterns in inflammatory arthritis. Proc Natl Acad Sci U S A (1994) 2.45
ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis (2008) 2.37
Differentiation of B cells in the nonlymphoid tissue of the synovial membrane of patients with rheumatoid arthritis. Proc Natl Acad Sci U S A (1996) 2.36
Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis (2004) 2.26
First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis (2005) 2.21
Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum (2003) 2.20
Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients. Arthritis Rheum (1994) 2.19
Idiotypic analysis of lymphocytes in vitro. I. Specificity and heterogeneity of B and T lymphocytes reactive with anti-idiotypic antibody. J Exp Med (1976) 2.05
No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial. Ann Rheum Dis (2006) 1.94
Antigen-driven clonal proliferation of B cells within the target tissue of an autoimmune disease. The salivary glands of patients with Sjögren's syndrome. J Clin Invest (1998) 1.92
Association of genotypes affecting the expression of interleukin-1beta or interleukin-1 receptor antagonist with osteoarthritis. Arthritis Rheum (2000) 1.88
Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial. Ann Rheum Dis (2006) 1.86
Radiologic diagnosis and pathology of the spondyloarthropathies. Rheum Dis Clin North Am (1998) 1.86
Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis- cellularity correlates with the degree of enhancement detected by magnetic resonance imaging. Ann Rheum Dis (2000) 1.85
[Therapy of ankylosing spondylitis (AS) with radium chloride (224SpondylAT)]. Z Rheumatol (2001) 1.82
Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology (Oxford) (2005) 1.82
Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis (2013) 1.81
Inflamed kidneys of NZB / W mice are a major site for the homeostasis of plasma cells. Eur J Immunol (2001) 1.80
The maturation of the immune response. Immunol Today (1993) 1.76
Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis (2004) 1.76
Idiotypic analysis of lymphocytes in vitro. II. Genetic control of T-helper cell responsiveness to anti-idiotypic antibody. J Exp Med (1976) 1.71
Plasma cell development in synovial germinal centers in patients with rheumatoid and reactive arthritis. J Immunol (1999) 1.71
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis (2007) 1.70
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis (2012) 1.67
On the structure of the T-cell receptor for antigen. Cold Spring Harb Symp Quant Biol (1977) 1.60
Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum (2005) 1.59
Infliximab treatment of severe ankylosing spondylitis: one-year followup. Arthritis Rheum (2001) 1.58
Analysing chronic spinal changes in ankylosing spondylitis: a systematic comparison of conventional x rays with magnetic resonance imaging using established and new scoring systems. Ann Rheum Dis (2004) 1.56
Activation of memory and virgin B cell clones in hyperimmune animals. Eur J Immunol (1987) 1.54
Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis. Ann Rheum Dis (2004) 1.53
Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis (2004) 1.53
Assessment of acute spinal inflammation in patients with ankylosing spondylitis by magnetic resonance imaging: a comparison between contrast enhanced T1 and short tau inversion recovery (STIR) sequences. Ann Rheum Dis (2005) 1.51
Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann Rheum Dis (2008) 1.49
Third International Workshop on Reactive Arthritis. 23-26 September 1995, Berlin, Germany. Report and abstracts. Ann Rheum Dis (1996) 1.47
Use of dynamic magnetic resonance imaging to detect sacroiliitis in HLA-B27 positive and negative children with juvenile arthritides. J Rheumatol (1998) 1.46
Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial. Ann Rheum Dis (2011) 1.46
Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes. Ann Rheum Dis (2007) 1.43
An idiotypic determinant formed by both immunoglobulin constant and variable regions. Nature (1983) 1.42
MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis. Ann Rheum Dis (2007) 1.40
Chlamydia pneumoniae--a new causative agent of reactive arthritis and undifferentiated oligoarthritis. Ann Rheum Dis (1994) 1.37
Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. Rheumatology (Oxford) (2004) 1.37
Overexpanded B cell clone mediating leukemic arthritis by abundant secretion of interleukin-1beta: a case report. Arthritis Rheum (1998) 1.37
Mendelian segregation of a mouse antibody idiotype. Eur J Immunol (1973) 1.37
The sacroiliac joint in the spondyloarthropathies. Curr Opin Rheumatol (1996) 1.37
Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab. Ann Rheum Dis (2005) 1.37
Three-dimensional structure of Fab R19.9, a monoclonal murine antibody specific for the p-azobenzenearsonate group. Proc Natl Acad Sci U S A (1989) 1.35
Somatic hypermutation in the absence of DNA-dependent protein kinase catalytic subunit (DNA-PK(cs)) or recombination-activating gene (RAG)1 activity. J Exp Med (2000) 1.34
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis (2010) 1.34
Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. Arthritis Rheum (2010) 1.33
Immunohistological analysis of cytokine expression in human osteoarthritic and healthy cartilage. J Rheumatol (1999) 1.33
Inflammation in ankylosing spondylitis: a systematic description of the extent and frequency of acute spinal changes using magnetic resonance imaging. Ann Rheum Dis (2004) 1.33
Current perspectives in reactive arthritis. Immunol Today (1993) 1.32
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis (2008) 1.31
Computed tomography guided corticosteroid injection of the sacroiliac joint in patients with spondyloarthropathy with sacroiliitis: clinical outcome and followup by dynamic magnetic resonance imaging. J Rheumatol (1996) 1.30
Anti-CD2 antibodies induce T cell unresponsiveness in vivo. J Exp Med (1991) 1.29
Anatomic structures involved in early- and late-stage sacroiliitis in spondylarthritis: a detailed analysis by contrast-enhanced magnetic resonance imaging. Arthritis Rheum (2003) 1.29
Low T cell production of TNFalpha and IFNgamma in ankylosing spondylitis: its relation to HLA-B27 and influence of the TNF-308 gene polymorphism. Ann Rheum Dis (2001) 1.29
Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum (2007) 1.28
CXCR5-deficient mice develop functional germinal centers in the splenic T cell zone. Eur J Immunol (2000) 1.27
Crucial role of interleukin-10/interleukin-12 balance in the regulation of the type 2 T helper cytokine response in reactive arthritis. Arthritis Rheum (1997) 1.27
Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data. Arthritis Rheum (2005) 1.25
Light chain germ-line genes and the immune response to 2-phenyloxazolone. EMBO J (1985) 1.24
Rheumatoid arthritis: evaluation of hypervascular and fibrous pannus with dynamic MR imaging enhanced with Gd-DTPA. Radiology (1990) 1.23
T cell cytokine pattern in the joints of patients with Lyme arthritis and its regulation by cytokines and anticytokines. Arthritis Rheum (1997) 1.23
The dynamic structure of the germinal center. Immunol Today (1998) 1.22
Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept. Ann Rheum Dis (2005) 1.21
Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study. Ann Rheum Dis (2011) 1.21
Development of antibody diversity in single germinal centers: selective expansion of high-affinity variants. Eur J Immunol (1994) 1.20
Enthesitis and ankylosis in spondyloarthropathy: what is the target of the immune response? Ann Rheum Dis (2000) 1.19
Biological therapies in the spondyloarthritides--the current state. Rheumatology (Oxford) (2004) 1.19
The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab. Clin Exp Rheumatol (2011) 1.19
[Recommendations for the management of ankylosing spodylitis after ASAS/EULAR. Evaluation in the German language area]. Z Rheumatol (2006) 1.18
Relationship between active inflammatory lesions in the spine and sacroiliac joints and new development of chronic lesions on whole-body MRI in early axial spondyloarthritis: results of the ESTHER trial at week 48. Ann Rheum Dis (2011) 1.18
B cells in rheumatoid arthritis. Arthritis Res (2000) 1.18
Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab. Rheumatology (Oxford) (2007) 1.18
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010. Ann Rheum Dis (2011) 1.17
Immunology of reactive arthritides. Annu Rev Immunol (1995) 1.17